Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.
about
Gallbladder Cancer in the 21st Century.Advances in systemic therapy for advanced pancreatobiliary malignanciesSurgical options for intrahepatic cholangiocarcinoma.Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decadesGemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trialsEfficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma.Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer.Chemotherapy and targeted therapy for gall bladder cancer.New insights on cholangiocarcinoma.Systemic Therapy of Cholangiocarcinoma.Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival.Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer.NCCN clinical practice guidelines in oncology: hepatobiliary cancersChemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis.SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.The role of chemotherapy in biliary tract carcinoma.EGFR and HER2 expression in advanced biliary tract cancer.Accomplishments in 2008 in the management of hepatobiliary cancers.Advances in the treatment of metastatic or unresectable biliary tract cancer.Chemotherapy for the biliary tract cancers: moving toward improved survival time.Advances in the management of biliary tract cancersTwenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity.Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patientsMultimodality treatment of intrahepatic cholangiocarcinoma: A review.Signaling pathways as therapeutic targets in biliary tract cancer.GUIDELINE FOR THE MANAGEMENT OF BILE DUCT CANCERS BY THE BRAZILIAN GASTROINTESTINAL TUMOR GROUP.Neoadjuvant chemotherapy in patients with locally advanced gallbladder cancer.Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.Reversal of jaundice in two patients with inoperable cholangiocarcinoma treated with Cisplatin and gemcitabine combination.A case of advanced intrahepatic cholangiocarcinoma accidentally, but successfully, treated with capecitabine plus oxaliplatin (CAPOX) therapy combined with bevacizumab: a case reportHepatic arterial infusion with oxaliplatin and 5-FU/folinic acid for advanced biliary tract cancer: a phase II study.Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells.Impact of Body Mass Index on Surgical and Oncological Outcomes in Laparoscopic Total Mesorectal Excision for Locally Advanced Rectal Cancer after Neoadjuvant 5-Fluorouracil-Based Chemoradiotherapy.Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
P2860
Q26784174-23370E1C-03D8-4374-91E6-19C3241A583EQ26822703-176E09A0-C8B8-4A7E-A23B-2A072B9CAA31Q30234462-6CBA6C4B-A9D2-44F2-9F90-75889FE152B5Q30300756-4C703A85-4B54-4989-AC16-F5CA8FB0C227Q30318857-07533415-3C56-4349-AFF0-CE2B41115AA1Q33381056-E6F2A9A2-F6E4-4824-A7FD-842CD85A82E8Q33395417-27EA56E1-3AC7-4054-8E16-F820E93699F4Q33399656-34BE03AF-880C-48FB-A5B2-580C3E3DD230Q33430668-C790A14B-034F-42B0-84C3-9C98281BE08CQ33721515-B3299C09-B15C-4BFB-A253-55246A13FDACQ33977171-37E028FA-4F2B-4828-9BC7-EDFB2FE25219Q34391135-D340ED4B-BFBC-4D35-BA5D-4D0B59AE07F6Q34551877-7FF64AD9-ED75-402E-8633-8DD652F4F126Q34623728-688BB31E-1F7B-4C70-B639-9C5080373548Q34627947-F88DBC36-EC0B-41D6-B9CC-C727F2E6DAE1Q35429914-09D74BEB-76CC-4A5C-89AB-0CD617AFC091Q35703937-1B813B83-70C9-473A-8050-087BCB33FCCAQ35715498-E6B27F65-5819-40C9-89CF-95CAD96D19F2Q36376264-9F5EACA9-D134-46D1-A9E4-05090D03B61CQ37111209-5377FC30-7B4E-41D1-BD45-5C5303104C7DQ37261360-77C75E59-C8DC-45E1-8597-0F40A16953FDQ37362858-82D12649-CA20-4B35-B83D-AE88C40CB08EQ37468851-89A6FF4A-104D-4882-9ECE-F28AC29FFB1FQ37799949-7B93E5FD-388F-48FC-A6FC-00F2CED359F6Q37983498-71B9C675-F74F-40BC-8EEE-9953C755795DQ38082318-49FD1890-39DB-4E70-95E4-336AA0FB236BQ38183813-B311B138-58E6-4273-BB2D-B3E42AD63980Q38662233-D729742B-E06D-4F4F-9F4E-9F4A7DE17147Q38669870-FB2A9628-DD07-40BA-81BE-9A0F89D08C50Q38707365-756D713E-3F9D-4979-9A96-D73249DF1F62Q38747573-3E3A926F-3467-48E0-A6BC-394DE72AC878Q38858942-E6325C15-321D-49D0-B27F-8C2C3E8B969CQ39008379-7C00735E-255F-471B-93E8-DA8AF28FE205Q39313846-5B3BDA12-923C-46BF-99F9-D5193E8DD726Q40008497-BE44E2DE-C983-48CB-BE39-E97E4264CBFFQ42019361-2EB678A0-9AA9-4F1D-900E-21F9358D4025Q42693724-BDC75AB7-18BC-45AE-98E7-BA3DD58C1DBDQ43196142-B3D97482-9321-49CE-B4D2-1783F104300FQ43290671-A9631C5F-6068-4D5D-ABDF-E2362B8B8A8DQ43589273-B48CD767-0985-43A4-89C0-114062859B37
P2860
Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Capecitabine plus oxaliplatin ...... ve multicentre phase II trial.
@ast
Capecitabine plus oxaliplatin ...... ve multicentre phase II trial.
@en
type
label
Capecitabine plus oxaliplatin ...... ve multicentre phase II trial.
@ast
Capecitabine plus oxaliplatin ...... ve multicentre phase II trial.
@en
prefLabel
Capecitabine plus oxaliplatin ...... ve multicentre phase II trial.
@ast
Capecitabine plus oxaliplatin ...... ve multicentre phase II trial.
@en
P2093
P2860
P921
P356
P1476
Capecitabine plus oxaliplatin ...... ve multicentre phase II trial.
@en
P2093
J T Hartmann
M S Horger
R-D Hofheinz
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604178
P407
P577
2008-01-08T00:00:00Z
P5875
P6179
1007336693